Home Cell Therapy CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy

CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy


ViaCyte’s attempts to develop a stem cell therapy for diabetes have been stymied by the immune system, which recognizes the implanted cells as foreign. Meanwhile, CRISPR Therapeutics has found success in gene-editing cells so that the cells avoid such immune responses.

Now the two companies are combining their respective technologies to develop a stem cell-based therapy that could effectively cure type 1 diabetes.

According to the agreement announced Monday, CRISPR (NASDAQ: CRSP) is set to pay San Diego-based ViaCyte $15 million in either cash or CRISPR stock. CRISPR has an additional option to pay $10 million more in the form of a convertible promissory note. Requirements for the additional payment were not specified.

ViaCyte has been trying to develop a type 1 diabetes treatment, using implanted stem cells engineered to grow into insulin-producing pancreatic cells, which would hopefully eliminate the need for daily insulin injections. These stem cells are delivered by implanting a membrane-bound device containing the cells.

Clinical trials testing this therapy, called PEC-Direct, started last year. The membrane allows blood vessels to grow through the device and reach the cells. ViaCyte says that while this approach could offer a long-lasting benefit, the immune system will still see the implanted stem cells as foreign and reject them. That means patients receiving this treatment will require long-term immunosuppression drugs. For that reason, ViaCyte has developed PEC-Direct for type 1 diabetes patients who face a high risk of complications.

ViaCyte wants to develop a version of its treatment that doesn’t require immune suppression and says that gene editing technology could protect transplanted stem cells from the immune system. CRISPR has already pursued a similar approach in its cancer cell therapy research. The Switzerland-based company, which has U.S. operations in Cambridge, MA, has three experimental “off-the-shelf” CAR-T treatments made by using its gene-editing technology to engineer donor T cells.

The collaboration calls for CRISPR and ViaCyte to work together to develop a stem cell line that can avoid attack from the immune system. If this research leads to a therapeutic candidate, the companies will share the responsibility for further development, and if approved, commercialization.

Previous articleAbeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
Next articleSQZ Biotech And Roche Expand Cell Therapy Partnership
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.